Literature DB >> 16012028

Digital hearing aids for high-frequency sensorineural hearing loss: preliminary experience with the RetroX device.

Maurizio Barbara1, Giorgio Bandiera, Bruno Serra, Vania Marrone, Silvia Tarentini, John C Pinna, Francesco Ronchetti, Marilena Graziadio, Simonetta Monini.   

Abstract

CONCLUSIONS: The RetroX outer ear hearing aid seems to represent a means of overcoming problems with understanding speech in noise in patients with high-frequency sensorineural hearing loss (SNHL) without the need to wear conventional completely-in-the-canal (CIC) hearing aids, which are usually reported to annoy patients as a result of the occlusion effect.
OBJECTIVE: To present preliminary data from a study carried out to compare the efficacy, in the same individual, of a standard digital CIC hearing aid and a new implantable outer ear canal device, the RetroX.
MATERIAL AND METHODS: Three out of 15 adults affected by high-frequency SNHL who were candidates for auditory rehabilitation were evaluated by using speech audiometric tests in quiet and noise as well as a questionnaire shortly after use of a CIC hearing aid and the RetroX device, i.e. at 7 and 14 days. The efficacy of the RetroX was anticipated by testing all the subjects using a RetroX simulating system before starting the study protocol.
RESULTS: In all three implanted patients, the RetroX provided better audiological benefit for speech understanding in noise. These findings were corroborated by the results of the questionnaire, which showed greater satisfaction with the RetroX, especially regarding the absence of the occlusion effect.

Entities:  

Mesh:

Year:  2005        PMID: 16012028     DOI: 10.1080/00016480510043396

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  A comparative study of the audiological outcomes with Retro-X (semi-implantable hearing aid system) and conventional open fitting hearing aids.

Authors:  Minoo Lenarz; Thomas Lenarz; Martin Stieve; Mark Winter
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-26       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.